Mercaptobenzimidazole-Based 1,3-Thaizolidin-4-ones as Antidiabetic Agents: Synthesis, in Vitro α-Glucosidase Inhibition Activity, and Molecular Docking Studies

13Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this research work, we have focused our efforts to synthesize a series of 2-mercaptobenzimidazole-based 1,3-thiazolidin-4-ones (5-24) following a multistep reaction strategy and characterization of the synthesized derivatives with the help of various spectroscopic techniques. To find the antidiabetic potentials of the synthesized compounds (5-24), in vitro alpha-glucosidase inhibitory activity was performed using acarbose (IC50= 873 ± 1.2 μM) as the reference standard. The results of the antidiabetic assay were very encouraging because compounds 5, 8, and 14 showed excellent inhibitions with IC50values of 5.22 ± 0.14, 5.69 ± 0.10, and 10.20 ± 0.12 μM, respectively. The experimental results of anti-alpha-glucosidase activity prompted us to investigate and propose a possible mechanism of how the active molecules will interact with the target enzyme. For this purpose, molecular docking with the AutoDock Vina (an open-source and reliable docking platform) gave us an insight into the binding interactions of the active compounds to different amino acid residues of the enzyme.

Cite

CITATION STYLE

APA

Khan, S. A., Ali, M., Latif, A., Ahmad, M., Khan, A., & Al-Harrasi, A. (2022). Mercaptobenzimidazole-Based 1,3-Thaizolidin-4-ones as Antidiabetic Agents: Synthesis, in Vitro α-Glucosidase Inhibition Activity, and Molecular Docking Studies. ACS Omega, 7(32), 28041–28051. https://doi.org/10.1021/acsomega.2c01969

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free